Xeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024. In the quarter to June 2026, revenue grew 28.7%, EPS fell 1,700.0%, free cash flow grew 8,403.1% and total debt rose 15.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow XERS
Xeris Biopharma Holdings, Inc. (XERS) EV/Sales
As of 16 October 2026, Xeris Biopharma Holdings, Inc. (XERS) trades at a EV/Sales of 5.7×. Over the past ten years it has ranged from −23.1× (September 2018) to 228× (November 2018); the current reading is higher than 65% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.7× | 45.98% |
| FY2024 | 3.2× | 22.57% |
| FY2023 | 2.6× | 33.35% |
| FY2022 | 2.0× | (55.35%) |
| FY2021 | 4.4× | (45.35%) |
| FY2020 | 8.1× | (86.98%) |
| FY2019 | 62.4× | 21.88% |
| FY2018 | 51.2× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.5× | 26.77% |
| Mar 2026 | 3.5× | (25.44%) |
| Dec 2025 | 4.7× | (14.47%) |
| Sep 2025 | 5.5× | 48.55% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRGO Perrigo Company plc compare | 1.3× |
| PAHC Phibro Animal Health Corporation compare | 1.5× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.8× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.6× |
| SUPN Supernus Pharmaceuticals, Inc. compare | 2.8× |
| PBH Prestige Consumer Healthcare Inc. compare | 3.9× |
| XERS Xeris Biopharma Holdings, Inc. | 5.7× |
| ALVO Alvotech compare | 9.0× |
| ETON Eton Pharmaceuticals, Inc. compare | 13.2× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)